Arcturus Therapeutics (ARCT) Tops Q3 EPS by 31c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q3 EPS of ($0.26), $0.31 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $41.67 million versus the consensus estimate of $53.46 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• AI/ML Innovations plans $2M private placement on the CSE
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results